Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Neuroleptic

or [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]]

Use the filters below to narrow your results.

Asenapine (1) · Brivaracetam (1) · Cannabidiol (1) · Cenobamate (1) · Chlorpromazine (1) · Clobazam (1) · Diltiazem (1) · Droperidol (1) · Eslicarbazepine (1) · Ethosuximide (1) · Felbamate (1) · Fenfluramine (1) · Fluphenazine (1) · Fosphenytoin (1) · Iloperidone (1) · Lacosamide (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Paliperidone (1) · Perampanel (1) · Perphenazine (1) · Phenobarbital (1) · Phenytoin (1) · Pimozide (1) · Rufinamide (1) · Stiripentol (1) · Thioridazine (1) · Thiothixene (1) · Tiagabine (1) · Trifluoperazine (1) · Valproic acid (1) · Verapamil (1) · Vigabatrin (1) · Ziprasidone (1) · Zonisamide (1)

Aptiom (1) · Banzel (1) · Briviact (1) · Calan, Calan SR, Verelan, Verelan PM, Isoptin SR (1) · Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA (1) · Cerebyx (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Epidiolex (1) · Fanapt (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Luminal (1) · Mellaril (1) · Moban (1) · Navane (1) · Onfi (1) · Orap (1) · Prolixin (1) · Sabril (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (1) · AMPA receptor antagonist (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Phenothiazine D2 antagonist (4) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)

None (34) · '"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"' (1) · '"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"' (1)

None (34) · ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) · IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1)

None (34) · IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL (1) · IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL (1)

None (34) · ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster (1) · ~480 mg/d (oral); IV per protocol (1)

None (34) · IV (2) · multiple ER formulations) (1) · Oral (IR (1) · Oral (IR and multiple ER) (1)

None (34) · IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours (1) · IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours (1)

None (34) · IR: 4-8 hours; ER: 24 hours (1) · IR: 6-8 hours; ER: 24 hours (1)

None (34) · 3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"' (1) · 3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"' (1)

None (34) · ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' (1) · ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' (1)

None (34) · Limited data; alternative antihypertensives generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited data; labetalol/nifedipine generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)